Briacell Therap (NASDAQ:BCTX) & ANI Pharmaceuticals (NASDAQ:ANIP) Financial Review

Briacell Therap (NASDAQ:BCTX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Institutional & Insider Ownership

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 76.0% of ANI Pharmaceuticals shares are held by institutional investors. 0.7% of Briacell Therap shares are held by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Briacell Therap has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Profitability

This table compares Briacell Therap and ANI Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

Earnings and Valuation

This table compares Briacell Therap and ANI Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31 million	($7.92)	-0.46
ANI Pharmaceuticals	$883.37 million	2.00	$78.34 million	$3.95	19.68

ANI Pharmaceuticals has higher revenue and earnings than Briacell Therap. Briacell Therap is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Briacell Therap and ANI Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1	0	0	0	1.00
ANI Pharmaceuticals	0	3	6	0	2.67

ANI Pharmaceuticals has a consensus target price of $105.00, suggesting a potential upside of 35.10%. Given ANI Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe ANI Pharmaceuticals is more favorable than Briacell Therap.

Summary

ANI Pharmaceuticals beats Briacell Therap on 12 of the 13 factors compared between the two stocks.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.